MX365914B - Forma de dosificación de topiramato dispersable rápidamente. - Google Patents

Forma de dosificación de topiramato dispersable rápidamente.

Info

Publication number
MX365914B
MX365914B MX2015012135A MX2015012135A MX365914B MX 365914 B MX365914 B MX 365914B MX 2015012135 A MX2015012135 A MX 2015012135A MX 2015012135 A MX2015012135 A MX 2015012135A MX 365914 B MX365914 B MX 365914B
Authority
MX
Mexico
Prior art keywords
topiramate
dosage form
rapidly dispersible
dispersible dosage
taste
Prior art date
Application number
MX2015012135A
Other languages
English (en)
Spanish (es)
Other versions
MX2015012135A (es
Inventor
Henry L Surprenant
Thomas G West
Jules Jacob
Donald C Monkhouse
Lauren Beach
Original Assignee
Aprecia Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprecia Pharmaceuticals LLC filed Critical Aprecia Pharmaceuticals LLC
Publication of MX2015012135A publication Critical patent/MX2015012135A/es
Publication of MX365914B publication Critical patent/MX365914B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2015012135A 2013-03-15 2014-03-14 Forma de dosificación de topiramato dispersable rápidamente. MX365914B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361791592P 2013-03-15 2013-03-15
PCT/US2014/029168 WO2014144661A1 (en) 2013-03-15 2014-03-14 Rapidly dispersible dosage form of topiramate

Publications (2)

Publication Number Publication Date
MX2015012135A MX2015012135A (es) 2015-11-25
MX365914B true MX365914B (es) 2019-06-20

Family

ID=51537752

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012135A MX365914B (es) 2013-03-15 2014-03-14 Forma de dosificación de topiramato dispersable rápidamente.

Country Status (10)

Country Link
US (2) US9492380B2 (cg-RX-API-DMAC7.html)
EP (1) EP2968181B1 (cg-RX-API-DMAC7.html)
JP (1) JP6466399B2 (cg-RX-API-DMAC7.html)
CN (1) CN105050588B (cg-RX-API-DMAC7.html)
AU (2) AU2014228861B2 (cg-RX-API-DMAC7.html)
CA (1) CA2906172C (cg-RX-API-DMAC7.html)
ES (1) ES2761407T3 (cg-RX-API-DMAC7.html)
HK (1) HK1213473A1 (cg-RX-API-DMAC7.html)
MX (1) MX365914B (cg-RX-API-DMAC7.html)
WO (1) WO2014144661A1 (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2187873T3 (pl) * 2007-08-13 2019-01-31 Abuse Deterrent Pharmaceutical Llc Leki odporne na nadużywanie, metoda stosowania i metoda wytwarzania
AU2014228990B2 (en) 2013-03-15 2017-02-02 Aprecia Pharmaceuticals LLC Rapid disperse dosage form containing levetiracetam
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
CN104586871B (zh) * 2014-12-27 2018-01-16 北京罗诺强施医药技术研发中心有限公司 包含托吡酯的药物组合物
US20160243036A1 (en) * 2015-02-25 2016-08-25 Intelgenx Corp. Film dosage forms containing amorphous active agents
KR20180014778A (ko) 2015-06-03 2018-02-09 트리아스텍 인코포레이티드 제형 및 이의 용도
WO2017175792A1 (ja) * 2016-04-06 2017-10-12 アステラス製薬株式会社 速溶出性三次元造形物、速溶出性三次元造形物用フィラメント及び速溶出性三次元造形物用材料
CA3035692C (en) 2016-09-02 2024-04-09 Novo Futura Ivs Disposable grill and method of manufacturing a disposable grill
CA3051614A1 (en) 2017-01-26 2018-08-02 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
CN107252418B (zh) * 2017-05-17 2020-06-23 西安棣加生物科技有限公司 一种3d打印技术制备治疗低钾血症的口腔速崩片的方法
CN107213126B (zh) * 2017-05-17 2020-06-23 西安棣加生物科技有限公司 一种3d打印技术制备治疗高磷血症的口腔速崩片的方法
US10703549B2 (en) * 2017-06-30 2020-07-07 The Procter And Gamble Company Water soluble containers and methods of making them
JP7719602B2 (ja) * 2017-11-02 2025-08-06 ザンボン エス．ピー．エー． サフィナミドを含む医薬組成物
WO2019131753A1 (ja) * 2017-12-26 2019-07-04 東和薬品株式会社 環状口腔内崩壊錠
CN116270513A (zh) 2018-01-09 2023-06-23 南京三迭纪医药科技有限公司 一种包含固定剂量adhd非兴奋剂和adhd兴奋剂的复方口服药物剂型
CN112218617A (zh) 2018-04-10 2021-01-12 潘纳西亚比奥马特斯公司 利用附加制造技术制备个性化营养配方和药物配方的方法和系统
CA3112618A1 (en) * 2018-09-14 2020-03-19 Merck Patent Gmbh Process for the preparation of a coated solid pharmaceutical dosage form
MX2021004318A (es) * 2018-10-15 2021-05-27 Aprecia Pharmaceuticals LLC Metodo y sistema para crear una forma de dosificacion dentro de un empaque.
WO2020104837A1 (en) 2018-11-21 2020-05-28 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
SG11202108659XA (en) 2019-02-22 2021-09-29 Catalent Uk Swindon Zydis Ltd Minimizing aeration of suspensions during in-line mixing
WO2020169992A1 (en) 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Minimizing agglomeration of drug particle coating material during storage to stabilize disintegration times of pharmaceutical products
WO2020169989A1 (en) 2019-02-22 2020-08-27 Catalent U.K. Swindon Zydis Limited Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
KR20210130720A (ko) 2019-02-22 2021-11-01 카탈렌트 유.케이. 스윈던 지디스 리미티드 수성 현탁액에서 무용매 혼합 공정에 의해 생성된 기능적으로-코팅된 api 입자 보존
EP4029380A4 (en) * 2019-09-13 2023-09-13 Meiji Co., Ltd SOLID FOOD AND SOLID MILK
MX2022016117A (es) 2020-06-26 2023-04-05 Aprecia Pharmaceuticals LLC Tabletas rapidamente orodispersables que tienen una cavidad interior.
CA3189404A1 (en) 2020-07-31 2022-02-03 Catalent U.K. Swindon Zydis Limited Pharmaceutical compositions comprising coated api
WO2024108082A1 (en) 2022-11-18 2024-05-23 Aprecia Pharmaceuticals LLC Orodispersive dosage forms containing droxidopa

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4642903A (en) 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4855326A (en) 1987-04-20 1989-08-08 Fuisz Pharmaceutical Ltd. Rapidly dissoluble medicinal dosage unit and method of manufacture
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5578322A (en) 1990-11-30 1996-11-26 Yamanouchi Pharmaceutical Co., Ltd. Quick release coated preparation
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5380473A (en) 1992-10-23 1995-01-10 Fuisz Technologies Ltd. Process for making shearform matrix
EP0804170B1 (en) 1993-07-09 2001-11-14 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5490962A (en) * 1993-10-18 1996-02-13 Massachusetts Institute Of Technology Preparation of medical devices by solid free-form fabrication methods
US5738875A (en) 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
EP0973507B1 (en) 1997-02-20 2009-01-21 Massachussets Institute of Technology Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
FR2766089B1 (fr) 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування
ATE265852T1 (de) 1999-07-09 2004-05-15 Ortho Mcneil Pharm Inc Geschmackskaschierte flüssige arzneizubereitungen
AU5060499A (en) * 1999-08-04 2001-03-05 Ranbaxy Laboratories Limited Hydrodynamically balanced oral drug delivery system
DE19940944B4 (de) 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
US7276252B2 (en) * 2000-05-18 2007-10-02 Massachusetts Institute Of Technology Method and form of a drug delivery device, such as encapsulating a toxic core within a non-toxic region in an oral dosage form
WO2003097018A1 (en) * 2002-02-04 2003-11-27 Ranbaxy Laboratories Limited Hydrodynamically balancing oral drug delivery system with biphasic release
AU2002254036A1 (en) 2001-03-05 2002-09-19 Ortho-Mcneil Pharmaceutical, Inc. Taste masked pharmaceutical compositions
WO2003037607A1 (en) * 2001-10-29 2003-05-08 Therics, Inc. A system and method for uniaxial compression of an article, such as a three-dimensionally printed dosage form
WO2003041690A2 (en) * 2001-10-29 2003-05-22 Therics, Inc. Three-dimensional suspension printing of dosage forms
FR2838647B1 (fr) 2002-04-23 2006-02-17 Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant
AU2003259417A1 (en) * 2002-09-04 2004-03-29 Ranbaxy Laboratories Limited Taste masked dosage forms and processes for their preparation
US20060159758A1 (en) 2002-12-11 2006-07-20 Rajesh Gandhi Coating composition for taste masking coating and methods for their application and use
EP1620075B1 (en) 2003-05-07 2020-06-24 Samyang Biopharmaceuticals Corporation Highly plastic granules for making fast melting tablets
FR2858556B1 (fr) 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
WO2005020961A1 (en) 2003-08-28 2005-03-10 Sandoz Ag Pharmaceutical composition comprising anticonvulsant with taste mask coating
JP2007517062A (ja) * 2003-12-29 2007-06-28 アルザ・コーポレーシヨン 機械的圧縮中に付着抵抗を与える薬物顆粒のコーティング
JP2008507508A (ja) * 2004-07-22 2008-03-13 株式會社アモーレパシフィック トピラメート徐放性製剤及びその製造方法
US20060127479A1 (en) 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
US20060182796A1 (en) 2005-02-03 2006-08-17 Abrika Pharmaceuticals, Inc. Taste masked pharmaceutical compositions
US20070092553A1 (en) 2005-10-21 2007-04-26 Pfab Lp Compositions and methods of making rapidly dissolving lonically masked formulations
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
CN102218044A (zh) * 2006-12-04 2011-10-19 苏佩努斯制药公司 托吡酯的增强的立即释放制剂
CN101842085B (zh) * 2007-10-31 2013-01-30 麦克内尔-Ppc股份有限公司 口腔崩解剂型
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
EP2397161B1 (en) 2009-02-12 2019-09-25 Fuji Chemical Industry Co., Ltd. Disintegrating particle composition and rapidly disintegrating compression-molded material comprising same
US20100285130A1 (en) 2009-05-06 2010-11-11 Monosol Rx, Llc Coating of complexed actives in film formulations
US20120076858A1 (en) 2009-06-04 2012-03-29 Basf Se Orally Disintegrating Dosage Forms Containing Taste-Masked Active Ingredients
US20120207836A1 (en) * 2009-08-19 2012-08-16 Bayer Pharma Aktiengesellschaft Drug delivery systems (wafer) for pediatric use
UY33173A (cg-RX-API-DMAC7.html) * 2010-01-08 2011-07-29 Eurand Inc
JP6133009B2 (ja) * 2010-08-11 2017-05-24 協和発酵キリン株式会社 トピラマート顆粒
US9381154B2 (en) * 2011-06-09 2016-07-05 Xerox Corporation Direct inkjet fabrication of drug delivery devices

Also Published As

Publication number Publication date
WO2014144661A1 (en) 2014-09-18
US9492380B2 (en) 2016-11-15
HK1214768A1 (en) 2016-08-05
ES2761407T3 (es) 2020-05-19
JP2016514686A (ja) 2016-05-23
US20150366801A1 (en) 2015-12-24
EP2968181A1 (en) 2016-01-20
EP2968181B1 (en) 2019-10-16
EP2968181A4 (en) 2016-04-13
WO2014144661A4 (en) 2014-11-13
CN105050588B (zh) 2019-01-15
WO2014144661A8 (en) 2015-08-27
JP6466399B2 (ja) 2019-02-06
AU2014228861A1 (en) 2015-10-08
AU2018220049B2 (en) 2020-07-09
CA2906172A1 (en) 2014-09-18
AU2018220049A1 (en) 2018-09-06
US20160361335A1 (en) 2016-12-15
HK1213473A1 (zh) 2016-07-08
CA2906172C (en) 2021-12-21
US10420785B2 (en) 2019-09-24
CN105050588A (zh) 2015-11-11
AU2014228861B2 (en) 2018-05-24
MX2015012135A (es) 2015-11-25

Similar Documents

Publication Publication Date Title
MX365914B (es) Forma de dosificación de topiramato dispersable rápidamente.
IL271352B (en) A pharmaceutical preparation containing a derivative of glutarimide and its use in the treatment of eosinophilic diseases
EP2967052A4 (en) COMPOSITIONS AND METHOD FOR IMMUNOMODULATION IN PLANTS
WO2011115725A3 (en) Indazole compounds as kinase activity modulators for the treatment of cancer and related disorders
EP3160493A4 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
TWD174792S (zh) 端蓋
PH12016500284B1 (en) Oral care composition
HUE055773T2 (hu) Epinefrin finom részecskék és módszerek azok alkalmazására az epinefrinre reagáló állapotok kezelésében
FR20C1026I1 (fr) Ciclesonide pour le traitement de maladies des voies respiratoires chez les chevaux
MY183106A (en) Fine dry particulate retinoid active agent compostions and topical formulations including the same
JP2016535794A5 (ja) 急速崩壊性固体剤形
MA55947A (fr) Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
PL2874600T3 (pl) Kompozycja farmaceutyczna do leczenia chrypki lub bólów gardła.
EP2964185A4 (en) PREPARATIONS FOR TREATMENT OF SLEEP RELATED ATMOSPHERES
EA201600412A1 (ru) Способ производства неорганического материала в виде частиц
FR2992219B1 (fr) Composition pour le traitement de l'hypocalcemie chez les ruminants
PH12017500763A1 (en) Nutritional compositions containing a prebiotic and lactoferrin and uses thereof
PH12017500062A1 (en) A water purification composition
AR095143A1 (es) Dispersión sólida que comprende cilostazol amorfo y proceso de preparación
MX368972B (es) Composiciones de glicoproteínas sialiladas y usos de estas.
GB201315072D0 (en) Novel compounds and pharmaceutical compositions thereoffor the treatment of proliferative disorders
AU2017260019A1 (en) Valerian composition and related methods
SG10201809280PA (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: APRECIA PHARMACEUTICALS LLC

FG Grant or registration